EA201071209A1 - Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови - Google Patents

Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови

Info

Publication number
EA201071209A1
EA201071209A1 EA201071209A EA201071209A EA201071209A1 EA 201071209 A1 EA201071209 A1 EA 201071209A1 EA 201071209 A EA201071209 A EA 201071209A EA 201071209 A EA201071209 A EA 201071209A EA 201071209 A1 EA201071209 A1 EA 201071209A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood
pharmaceutically acceptable
acceptable salt
drunedaron
kalium
Prior art date
Application number
EA201071209A
Other languages
English (en)
Inventor
Кристоф Годэн
Насера Амдани
Давиде Радзик
Мартин Ван Айкельс
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40001356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071209(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA201071209A1 publication Critical patent/EA201071209A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для применения в регуляции уровня калия в крови.
EA201071209A 2008-04-18 2009-04-16 Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови EA201071209A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4599508P 2008-04-18 2008-04-18
FR0803525A FR2930150B1 (fr) 2008-06-24 2008-06-24 Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
PCT/IB2009/005605 WO2009144551A2 (en) 2008-04-18 2009-04-16 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood

Publications (1)

Publication Number Publication Date
EA201071209A1 true EA201071209A1 (ru) 2011-04-29

Family

ID=40001356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071209A EA201071209A1 (ru) 2008-04-18 2009-04-16 Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови

Country Status (26)

Country Link
US (1) US20110124724A1 (ru)
EP (1) EP2280702A2 (ru)
JP (1) JP2011518147A (ru)
KR (1) KR20100135814A (ru)
CN (1) CN102065857A (ru)
AR (1) AR072951A1 (ru)
AU (1) AU2009252898A1 (ru)
BR (1) BRPI0911198A2 (ru)
CA (1) CA2721491A1 (ru)
CL (1) CL2009000919A1 (ru)
CO (1) CO6260065A2 (ru)
CR (1) CR11734A (ru)
DO (1) DOP2010000300A (ru)
EA (1) EA201071209A1 (ru)
EC (1) ECSP10010553A (ru)
FR (1) FR2930150B1 (ru)
IL (1) IL208751A0 (ru)
MA (1) MA32356B1 (ru)
MX (1) MX2010011400A (ru)
NI (1) NI201000173A (ru)
PE (1) PE20091777A1 (ru)
SV (1) SV2010003701A (ru)
TW (1) TW200946108A (ru)
UY (1) UY31768A (ru)
WO (1) WO2009144551A2 (ru)
ZA (1) ZA201007391B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135909A (ko) * 2008-04-17 2010-12-27 사노피-아벤티스 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
PL2852385T3 (pl) 2012-05-22 2020-03-31 Sanofi Dronedaron do zastosowania w leiszmaniozie, formulacje i połączenia do stosowania w leiszmaniozie
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
US20080234337A1 (en) * 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
FR2930148A1 (fr) * 2008-04-17 2009-10-23 Sanofi Aventis Sa Utilisation de la dronedarone pour la preparation d'un medicament destine a la prevention de l'hospitalisation cardiovasculaire ou de la mortalite
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang

Also Published As

Publication number Publication date
DOP2010000300A (es) 2010-11-15
CL2009000919A1 (es) 2010-04-09
CA2721491A1 (en) 2009-12-03
CR11734A (es) 2010-12-09
IL208751A0 (en) 2010-12-30
KR20100135814A (ko) 2010-12-27
PE20091777A1 (es) 2009-12-04
UY31768A (es) 2009-12-14
MX2010011400A (es) 2010-11-12
ECSP10010553A (es) 2010-11-30
US20110124724A1 (en) 2011-05-26
TW200946108A (en) 2009-11-16
CO6260065A2 (es) 2011-03-22
NI201000173A (es) 2011-07-20
EP2280702A2 (en) 2011-02-09
BRPI0911198A2 (pt) 2015-10-13
FR2930150B1 (fr) 2011-01-14
JP2011518147A (ja) 2011-06-23
ZA201007391B (en) 2012-01-25
WO2009144551A2 (en) 2009-12-03
CN102065857A (zh) 2011-05-18
FR2930150A1 (fr) 2009-10-23
AU2009252898A1 (en) 2009-12-03
SV2010003701A (es) 2011-01-31
AR072951A1 (es) 2010-10-06
MA32356B1 (fr) 2011-06-01
WO2009144551A3 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
IN2012DN06720A (ru)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
CL2017000494A1 (es) Tratamientos médicos a base de anamorelina.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
EA200970816A1 (ru) Новая лекарственная форма
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом